These Analysts Raise Their Forecasts On Axos Financial After Earnings Beat

Axos Financial, Inc. (NYSE: AX) reported better-than-expected second-quarter results on Tuesday.

Axos Financial, Inc. (NYSE:AX) reported better-than-expected second-quarter results on Tuesday.

Axos Financial posted adjusted earnings of $1.60 per share, beating market estimates of $1.38 per share. The company’s quarterly sales came in at $352.74 million versus expectations of $247.50 million, according to data from Benzinga Pro.

Net interest margin increased to 4.55% for the quarter ended Dec. 31, 2023, versus 4.49% for the year-ago quarter.

Net loans for investment came in at $18.3 billion at Dec. 31, 2023, versus $16.5 billion at June 30, 2023.

“Our record second quarter earnings were driven by strong organic loan and deposit growth, further net interest margin expansion, disciplined expense management and a gain associated with an opportunistic loan purchase from the FDIC,” stated Greg Garrabrants, President and Chief Executive Officer of Axos. “Excluding the one-time gain and the provision for credit losses associated with the FDIC Loan Purchase, diluted EPS was up 15.7% year-over-year. Our strong returns, margins and excess capital provide us with flexibility to allocate capital to opportunities where we see the best risk-adjusted returns.”

Axos Financial shares gained 1% to $57.35 in pre-market trading.

These analysts made changes to their price targets on Axos Financial after the company reported quarterly results.

  • Raymond James boosted the price target on Axos Financial from $45 to $62. Raymond James analyst David Feaster maintained an Outperform rating.
  • Wedbush increased Axos Financial price target from $59 to $62. Wedbush analyst David Chiaverini maintained a Neutral rating.

Read This Next: Alphabet, Boeing And 3 Stocks To Watch Heading Into Wednesday

Total
0
Shares
Related Posts
Read More

Prophase Labs’ Prophase Labs Will Acquiring New Equipment Which Is Expected To Double Its Current Capacity For Pouch Packaging By Q2 Of 2023. Pharmaloz Is Also Planning For Expansion Of Its Lozenge Manufacturing Business

Altogether, these expansion initiatives are expected to lead to a 200% increase in capacity for 2024 as compared to 2022. It is currently expected that the Pharmaloz expansion will be funded entirely from

PRPH